{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:02:10Z","timestamp":1789768930262,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.urolonc.2026.08.015","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:19:03Z","timestamp":1789766343000},"page":"873-886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen"],"prefix":"10.1016","volume":"44","author":[{"given":"Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaikai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1472-7524","authenticated-orcid":false,"given":"Haibo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2026.08.015_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.015_bib0002","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.015_bib0003","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.015_bib0004","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","article-title":"Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes","volume":"69","author":"Dobruch","year":"2016","journal-title":"Eur Urol"},{"issue":"19","key":"10.1016\/j.urolonc.2026.08.015_bib0005","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.015_bib0006","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41585-022-00693-z","article-title":"Health-related quality of life after curative treatment for muscle-invasive bladder cancer","volume":"20","author":"Grobet-Jeandin","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.015_bib0007","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2012.11.015","article-title":"Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base","volume":"63","author":"Gray","year":"2013","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.015_bib0008","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajur.2015.04.016","article-title":"Current status of diagnosis and treatment of bladder cancer in China - analyses of Chinese Bladder Cancer Consortium database","volume":"2","author":"Li","year":"2015","journal-title":"Asian J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.015_bib0009","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.015_bib0010","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"issue":"16","key":"10.1016\/j.urolonc.2026.08.015_bib0011","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.urolonc.2026.08.015_bib0012","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.015_bib0013","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.08.015_bib0014","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.urolonc.2026.08.015_bib0015","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1464-410X.2009.09190.x","article-title":"Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder","volume":"106","author":"Bolenz","year":"2010","journal-title":"BJU Int"},{"issue":"32","key":"10.1016\/j.urolonc.2026.08.015_bib0016","article-title":"A HER2-targeted antibody-drug conjugate, RC48-ADC, exerted promising antitumor efficacy and safety with intravesical instillation in preclinical models of bladder cancer","volume":"10","author":"Hong","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.015_bib0017","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.015_bib0018","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.08.015_bib0019","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4568","article-title":"Preliminary efficacy and safety results from RC48-C017: a phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"10.1016\/j.urolonc.2026.08.015_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.665","article-title":"Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: updated efficacy and safety results from the phase II RC48-C017 trial","volume":"43","author":"Sheng","year":"2025","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.urolonc.2026.08.015_bib0021","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.urolonc.2026.08.015_bib0022","first-page":"12929","article-title":"Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery","volume":"24","author":"Li","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.015_bib0023","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.urolonc.2026.08.015_bib0024","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus Toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:19:11Z","timestamp":1789766351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926007106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1078143926007106"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.015","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}